SELLAS Life Sciences closed a $172.5 million public offering of common stock to advance its cancer therapy developments.
Quiver AI Summary
SELLAS Life Sciences Group, Inc. announced the successful closing of its underwritten public offering, selling 13,269,231 shares of common stock at $13.00 per share, resulting in gross proceeds of $172.5 million. This offering included the full exercise of an option by underwriters to purchase an additional 1,730,769 shares and attracted new healthcare-focused institutional investors. The offering was managed by J.P. Morgan and TD Cowen, with other firms involved as managers. The shares were made available under a shelf registration statement filed with the SEC. SELLAS, which develops novel cancer therapies including its lead candidate GPS, aims to address various malignancies and continues to face the challenges inherent in oncology product development.
Potential Positives
- SELLAS Life Sciences successfully closed a public offering, raising $172.5 million, which enhances its financial resources for further development of cancer therapies.
- The offering's inclusion of new healthcare-focused institutional investors indicates growing investor confidence and interest in SELLAS' clinical developments.
- The successful exercise of the underwriters' option to purchase additional shares demonstrates strong demand for the offering, reflecting positively on the company's market position.
Potential Negatives
- The issuance of a significant number of shares (13,269,231) may dilute existing shareholders' equity, potentially leading to a loss of confidence among current investors.
- The need for an underwritten public offering may indicate financial instability or a lack of sufficient capital for ongoing operations and development, raising concerns about the company's financial health.
- The forward-looking statements in the release highlight inherent risks and uncertainties associated with the company's product development and regulatory approval, which may deter potential investors.
FAQ
What was the total gross amount raised by SELLAS Life Sciences in its recent public offering?
SELLAS raised a total of $172.5 million from its recent underwritten public offering.
Who acted as lead managers for the SELLAS public offering?
J.P. Morgan and TD Cowen were the lead book-running managers, with Mizuho as a book-running manager.
What is the focus of SELLAS Life Sciences Group?
SELLAS focuses on developing novel therapies for a wide range of cancer indications.
Where can I find the SEC filings related to this offering?
The SEC filings, including the prospectus, can be found on the SEC’s website at http://www.sec.gov.
What is the lead product candidate of SELLAS Life Sciences?
SELLAS' lead product candidate is GPS, which targets the WT1 protein in various tumor types.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SLS Hedge Fund Activity
We have seen 146 institutional investors add shares of $SLS stock to their portfolio, and 82 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ANSON FUNDS MANAGEMENT LP removed 4,500,000 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $55,395,000
- CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM removed 2,760,241 shares (-92.4%) from their portfolio in Q3 2026, for an estimated $33,978,566
- STATE STREET CORP removed 2,623,484 shares (-20.2%) from their portfolio in Q3 2026, for an estimated $32,295,088
- JONES FINANCIAL COMPANIES LLLP removed 2,161,983 shares (-93.8%) from their portfolio in Q3 2026, for an estimated $26,614,010
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 1,236,571 shares (+218.9%) to their portfolio in Q3 2026, for an estimated $15,222,189
- BLACKROCK, INC. added 1,111,332 shares (+7.4%) to their portfolio in Q3 2026, for an estimated $13,680,496
- BNP PARIBAS FINANCIAL MARKETS removed 1,009,969 shares (-94.2%) from their portfolio in Q3 2026, for an estimated $12,432,718
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
NEW YORK, Nov. 20, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the closing of its previously announced underwritten public offering of 13,269,231 shares of its common stock at a public offering price of $13.00 per share, which includes the exercise in full by the underwriters of their option to purchase 1,730,769 additional shares of common stock. The aggregate gross proceeds to SELLAS from this offering were $172.5 million before deducting underwriting discounts and commissions and offering expenses. Investors in the offering included new healthcare-focused institutional investors.
J.P. Morgan and TD Cowen acted as the lead book-running managers for the offering. Mizuho also acted as a book-running manager for the offering. A.G.P./Alliance Global Partners and Maxim Group LLC acted as lead managers for the offering.
The public offering was made pursuant to a shelf registration statement on Form S-3 (File No. 333-294504) that was previously filed with the Securities and Exchange Commission (the “SEC”) on March 20, 2026, and became automatically effective upon filing. The preliminary prospectus supplement and accompanying base prospectus and the final prospectus supplement relating to and describing the terms of the offering have been filed with the SEC and are available on the SEC’s website located at http://www.sec.gov. The offering was made only by means of a prospectus and related prospectus supplement, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected]; or TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected] .
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib), a small molecule CDK9 inhibitor, for the treatment of AML in patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the public offering. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties, including the risks and uncertainties inherent in SELLAS’ business, including those described in the company’s periodic filings with the SEC. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 19, 2026 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.
Investor Contact
John Fraunces
Managing Director
LifeSci Advisors, LLC
[email protected]
Media Contact
Joan Bosisio
VP, Scientific & Medical Communications
Simpson Healthcare
[email protected]
Source: SELLAS Life Sciences Group, Inc.